Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411801 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study, sponsored by Octapharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT00411801 is a Phase 3 study that was terminated before completion, run by Octapharma. The registered enrollment target is 8 participants.
The verdict
NCT00411801, a Phase 3 study, was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a universally applicable human plasma, which can be administered irrespective of the patient's blood group. This study will test the safety and efficacy of Uniplas in comparison to cryosupernatant plasma in treatment of patients with TTP.
Interventions
- BIOLOGICAL Uniplas
- BIOLOGICAL Cryosupernatant plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411801
The ClinicalTrials.gov registry entry for NCT00411801 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Uniplas is the first listed.
NCT00411801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411801 about?
NCT00411801 is a clinical study titled "Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)". Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a u...
What is the current status of trial NCT00411801?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00411801?
The interventions under investigation include: Uniplas (BIOLOGICAL), Cryosupernatant plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00411801?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.